中文

← All funding rounds

PerturbMind

Also known as PerturbMind AI

ChinaDrug discoveryChinaPrivate

Builds AlphaCell, a model meant to predict how a cell's gene expression changes when a gene or a drug perturbs it, to help find disease mechanisms, new targets and new kinds of drugs; it plans to sell on-device service subscriptions and private deployments and to co-run drug programmes.

Disclosed total-
Rounds on record1
Latest roundtens of millions of yuanAngel and Angel+ · 2026-10-29
Last stated valuationNone stated
Investors named2
Research on recordNone yet

Money and evidence

Moneyeach round in US dollars; ≈ converted at its dateAngel and Angel+
Closed roundNot on the dollar scale (a range, or no rate)

No research by this company is on the record yet.

Rounds and research, on one timeline

  1. 2026-10-29Angel and Angel+
    Round

    tens of millions of yuan

    For: not stated; the company released AlphaCell 1.0 Pro with the news and plans on-device service subscriptions, private deployments and co-run drug programmes

    Not stated

    Zhidx reported on 30 October that the company announced the rounds the day before, quoting CEO Guohui Chuai and chief scientist Qi Liu. Several drug companies also followed on, unnamed. No valuation. Qingsong Capital and Tongyang Fund are pinyin of the names the source gives.

    Lead · Qingsong CapitalTongyang Fund

    Announced by the company · tech.ifeng.com ↗On the timeline →

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →